+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of tilrekimig, a study medicine being tested for severe asthma. The trial focuses on people who have had severe asthma for at least 12 months and experienced two or more asthma attacks in the past year. This phase 3 study aims to understand how tilrekimig compares to placebo shots in improving asthma symptoms and reducing attack rates. Participants will receive either tilrekimig or a placebo through subcutaneous injections administered at the study clinic. The study uses a randomized, double-blind design with parallel groups to compare outcomes. Treatment and observation take place over a 52-week period, with additional monitoring of safety up to 64 weeks. During the study, participants will have regular assessments including lung function tests, symptom questionnaires, and monitoring for asthma exacerbations and safety events. Researchers will measure the annual rate of asthma attacks, lung function changes, quality of life, and other asthma control indicators. The total duration for participant involvement is up to 64 weeks, including follow-up for adverse events.

Age: 12Years - 80YearsAll GendersPhase 3
16 locations
P

Actively Recruiting

Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.

All AgesAll GendersPhase 3
629 locations
N

Actively Recruiting

Researchers are investigating whether adding preoperative chemotherapy to surgery improves the outcomes for patients with high risk retroperitoneal sarcoma, specifically dedifferentiated liposarcoma DDLPS and leiomyosarcoma LMS. This phase III randomized trial compares the effects of surgery alone versus surgery following chemotherapy on disease-free survival in these patients. Participants are assigned to one of two groups the standard treatment group, which undergoes large en-bloc curative-intent surgery within four weeks after randomization, or the experimental group, which receives three cycles of chemotherapy before surgery. Chemotherapy regimens differ by sarcoma type, with high grade LPS patients receiving doxorubicin plus ifosfamide every three weeks, and LMS patients receiving doxorubicin plus dacarbazine every three weeks. Surgery is then scheduled 3 to 6 weeks after the last chemotherapy cycle, with doses adapted per institutional guidelines. During the study, participants undergo imaging assessments to evaluate tumor operability and response to treatment. Researchers monitor disease-free survival over seven years from the first patient enrolled, along with secondary outcomes including overall survival, recurrence, metastasis rates, treatment safety, quality of life, and pathological response. Participants are closely followed through scheduled visits and tests to assess treatment effects and potential complications until study completion in 2028.

Age: 18Years +All GendersPhase 3
176 locations